Skip to main content

CORRECTION

Pathol. Oncol. Res., 30 January 2023
Volume 29 - 2023 | https://doi.org/10.3389/pore.2023.1610989

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

Yu-Ting Ma&#x;Yu-Ting Ma1‡Yan Li&#x;Yan Li2‡Li Yan&#x;Li Yan3‡Fang HuaFang Hua4Dong-Guan WangDong-Guan Wang3Guo-Ying XuGuo-Ying Xu5Hong-Lan YangHong-Lan Yang2Ying-Jie XueYing-Jie Xue1Ye-Jun QinYe-Jun Qin1Dan ShaDan Sha6Hao NingHao Ning7Miao-Qing Zhao Miao-Qing Zhao8*Zhi-Gang Yao &#x;Zhi-Gang Yao1*†
  • 1Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
  • 2Departmentof Oncology, Dongying City People’s Hospital, Dongying, China
  • 3Department of Pathology, Dongying City People’s Hospital, Dongying, China
  • 4Department of Microbiology and Immunology, Tulane University, New Orleans, LA, United States
  • 5Department of Urology Surgery, Dongying Hospital of Traditional Chinese Medicine, Dongying, China
  • 6Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
  • 7Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
  • 8Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

A Corrigendum on
Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

by Ma Y-T, Li Y, Yan L, Hua F, Wang D-G, Xu G-Y, Yang H-L, Xue Y-J, Qin Y-J, Sha D, Ning H, Zhao M-Q and Yao Z-G (2022). Pathol Oncol Res. 28:1610638. doi: 10.3389/pore.2022.1610638

In the published article there was an error in the author list. Authors Hong-Lan Yang and Yan Li were listed in the wrong order. The equal contribution of the first co-authors was not included. The corrected author list appears below:

Yu-Ting Ma1‡, Yan Li2‡, Li Yan3‡, Fang Hua4, Dong-Guan Wang3, Guo-Ying Xu5, Hong-Lan Yang2, Ying-Jie Xue1, Ye-Jun Qin1, Dan Sha6, Hao Ning7, Miao-Qing Zhao8* and Zhi-Gang Yao1*†

†ORCID: Zhi-Gang Yao, orcid.org/0000-0002-8034-6524

‡Contributed equally to this work

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: immunotherapy, microsatellite instability, immune checkpoint inhibitors, urothelial carcinoma, lynch syndrome, PD-1/PD-L1

Citation: Ma Y-T, Li Y, Yan L, Hua F, Wang D-G, Xu G-Y, Yang H-L, Xue Y-J, Qin Y-J, Sha D, Ning H, Zhao M-Q and Yao Z-G (2023) Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma. Pathol. Oncol. Res. 29:1610989. doi: 10.3389/pore.2023.1610989

Received: 04 December 2022; Accepted: 12 January 2023;
Published: 30 January 2023.

Edited by:

Pathology & Oncology Research Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Ma, Li, Yan, Hua, Wang, Xu, Yang, Xue, Qin, Sha, Ning, Zhao and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhi-Gang Yao, yzg20062009@163.com; Miao-Qing Zhao, zhaomqsd@163.com

†ORCID: Zhi-Gang Yao, orcid.org/0000-0002-8034-6524

‡These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.